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Roberto Bolli, MD, Shahab Ghafghazi, MDSEE PAGE 1990C ell therapy, arguably the most exciting ﬁeldof research in contemporary cardiovascularmedicine, is mired in controversy and uncer-
tainty (1,2). One of the major obstacles to progress is
the paucity of rigorous translational studies, particu-
larly studies in large animals (1). Understandably, the
initial evaluation of new cell therapies is usually con-
ducted in rodents, but what should come next?
Assessing every new type of cells in humans would
not be safe, practical, or cost-effective. Before moving
to clinical trials, promising cell types must be evalu-
ated in clinically relevant, large animal models.
At present, however, the majority of research dol-
lars allocated to preclinical trials of cardiac rege-
neration subsidize studies in rodents; only a small
minority of available grants supports translational
work in large animal models that are more relevant to
humans. As a result, most of the preclinical knowl-
edge is predicated on data obtained in rodents,
particularly mice. Murine models are relatively cheap
and quick and lend themselves to genetic manipula-
tions, but are they relevant to humans? Are the ef-
fects of stem/progenitor cells the same in mice and
humans? The answers to these questions are un-
known. Evidence that murine models are similar to
the human situation is scarce; if anything, there is
considerable evidence to the contrary. For example,
mice and humans, separated by 65 to 100 million
years of evolution, differ signiﬁcantly with respect
to innate and adaptive immunity (3), sarcomeric*Editorials published in the Journal of the American College of Cardiology
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in humans vs. MYH6 isoform in mice), and ion
channels (e.g., mice lack IKr), not to mention the
gargantuan inﬂuence of genetic backgrounds in
different murine strains. Human hearts do not beat
500 to 700 times/min, and repair of human myo-
cardial infarctions requires replacement of several
grams of dead tissue, not a few milligrams. Given
these enormous differences, the willingness of some
investigators (as well as the lay public and media) to
readily extrapolate murine data to humans is,
indeed, surprising. For example, mouse studies have
been glibly used as a basis for recommending that
clinical trials of cell therapy be stopped, which
would be irrational. Of course, murine models can be
useful as screening tools and to interrogate molec-
ular mechanisms, but one must always keep in mind
that the actions of stem/progenitor cells may be
completely different in humans.Given the obvious limitations of murine models, it
is crucial for the progress of the ﬁeld that cell therapy
be studied in large animal models that are closer to
the clinical setting. In this issue of the Journal,
Karantalis et al. (4) report that the combination of
mesenchymal stem cells (MSCs) and c-kitþ cardiac
progenitor cells (CPCs) was superior to MSCs alone in
improving global left ventricular (LV) performance in
a porcine model of chronic ischemic cardiomyopathy;
both treatments, however, achieved a similar im-
provement in wall motion in the infarct zone and a
similar reduction in scar size. This group had previ-
ously found that human CPCs and human MSCs have
additive effects in repairing infarcted myocardium in
pigs (5). Compared with that earlier study, the pre-
sent research is a signiﬁcant advance because of
several aspects that increase the clinical relevance of
the observations. First, the authors used autologous
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2001porcine cells as opposed to xenogeneic human cells,
thereby obviating the need for immunosuppression,
which could alter the response of the host to the
transplanted cells and has no clinical correlate.
Second, the cells were delivered transendocardially
with the NOGA system for electroanatomic mapping
(Biosense Webster, Inc., Diamond Bar, California) as
opposed to the transepicardial route (6), which is not
feasible or practical in most patients. Third, the cells
were transplanted 3 months after myocardial
infarction (MI) as opposed to 2 weeks after MI; that
is, cell therapy was performed in a setting that
simulates chronic ischemic cardiomyopathy rather
than acute or subacute MI. An important strength of
this study is that it was conducted in a well-
established porcine model (7), with the use of
state-of-the-art methods and a demanding protocol
lasting 6 months. Taken together, the ﬁndings of
Karantalis et al. (4) provide further evidence that
combining MSCs with CPCs results in greater efﬁcacy
than using MSCs alone for the treatment of post-MI
LV remodeling and dysfunction, even when the
healing process is complete and the disease has
entered its chronic phase.
The ﬁndings of Karantalis et al. (4) have clear
therapeutic implications. Phase I clinical studies have
suggested that both CPCs (8) and MSCs (9) alleviate
LV dysfunction, reduce scar size, or both; if the re-
sults of the present study are applicable to humans,
the effectiveness of cell therapy in patients with
chronic ischemic heart failure would be enhanced. In
conjunction with a previous study by this group (5),
the observations of Karantalis et al. reinforce the
rationale for the soon-to-be-initiated CONCERT-HF
(Combination of Mesenchymal and C-kitþ Cardiac
Stem Cells as Regenerative Therapy for Heart Failure
[NCT02501811]), a Phase II trial by the Cardiovascular
Cell Therapy Research Network that will compare the
safety, feasibility, and efﬁcacy of MSCs alone, CPCs
alone, and their combination in patients with
ischemic cardiomyopathy.
Few studies have combined 2 cell types at the
experimental level (5,10–18) and none at the clinical
level (Table 1). In general, these studies found that
combination therapy was superior to single-cell
therapy. As indicated earlier, Williams et al. (5)
administered human CPCs, human MSCs, or their
combination in a swine model of subacute MI. Left
ventricular ejection fraction was restored to baseline
with both single and combination therapy. However,
the reduction in infarct size was double with combi-
nation therapy compared with single-cell therapy; in
addition, the engraftment of transplanted cells was
7-fold greater with the combination therapy than witheither cell type alone. Using human saphenous vein–
derived pericyte progenitors (a subtype of MSCs) and
CPCs in a murine model of acute MI, Avolio et al. (10)
showed that both single-cell and dual-cell therapy led
to an improvement in left ventricular ejection frac-
tion and a reduction in interstitial ﬁbrosis; however,
only the combination therapy resulted in a reduction
in infarct size and an increase in arteriogenesis
compared with vehicle. Similarly, Winter et al. (11)
reported that the combination of epicardial-derived
cells and cardiomyocyte progenitor cells was supe-
rior to single-cell therapy. In yet another study,
Latham et al. (12) demonstrated in a murine model of
acute MI that the combination of human circulatory
angiogenic cells and cardiac stem cells resulted in
greater improvement in left ventricular ejection
fraction, a reduction in infarct size, and an improve-
ment in capillary density compared with single-cell
therapy. The positive interaction between 2 cell
types reported in these studies (5,10–18) was pre-
sumably the result of paracrine mechanisms. Taken
together, the present report (1) and these previous
studies (5,10–18) support the concept that combina-
torial therapy is likely to be superior to single-cell
therapy, and it should therefore be one of the main
avenues for future research.
The work of Karantalis et al. (4) is also important
because it epitomizes rigorous translational research.
Translational studies in large animal models (usually
pigs) are rare because they are expensive, complex,
time-consuming, technically demanding, slow, and
usually not suitable for mechanistic investigations;
nevertheless, because they are conducted in settings
closer to the human situation than those found
in rodent models, these studies are essential to
justify the risks and costs of clinical trials. Unfortu-
nately, the added value of the clinical relevance
of large animal models is often not appreciated by
reviewers of manuscripts and grant applications,
who assign low scores on the basis of lack of
mechanistic insights and insufﬁcient conceptual
novelty. For cell therapy to be translated into clinical
therapies, it is critical that this misperception be
corrected.
It is also critical that access to large animal models
be available to the entire scientiﬁc community
because very few investigators have the expertise
necessary to use such models successfully. While the
number of molecular and cellular biologists working
on stem/progenitor cells continues to increase, the
number of integrative physiologists continues to
decrease inexorably. These considerations provide a
cogent rationale for the National Institutes of Health
to establish a national consortium of core laboratories
TABLE 1 Summary of Experimental Studies of Combination Cell Therapy
First Author (Ref. #) Host
Type of Heart
Disease Study Groups
No. of Animals
per Group
Time of Cell
Therapy
Dose and Route of
Administration
Follow-up Period
After Cell Therapy
Final Assessment
Modality Outcome
Williams et al. (5) Yorkshire
pigs
Subacute MI hMSCs; hCPCs; both
hMSCs and
hCPCs; placebo
5 2 weeks after MI Intramyocardial via
minithoracotomy;
hMSCs 2  108; hCPCs
1  106; dual therapy
included both the
above doses
4 and 6 weeks MRI
Micromanometer
Conductance
Catheterization
EF [ in all cell groups
Infarct size Y in all cell groups
(dual therapy > single
therapy)
Diastolic function [ in dual
therapy > single therapy
Stem cell engraftment[ in dual
therapy >> single therapy
Contractility (preload
recruitable stroke work and
dP/dtmax) [ in dual therapy
> single therapy
Avolio et al. (10) SCID-beige
mice
Acute MI hSVPs; hCPCs; both
hSVPs and hCPCs;
vehicle; sham
5–7 At the time
of MI
Intramyocardial via
thoracotomy; hSVPs
3  105; hCPCs 3 
105; dual therapy
included both the
above doses
2 and 6 weeks Echocardiography
Intraventricular
pressure
measurement
EF [, interstitial ﬁbrosis Y in
all cell groups
LV remodeling Y in dual therapy
and hCPC group
Stem cell engraftment in
dual therapy4
Infarct size Y and arteriogenesis
[ in dual therapy >
single therapy
Winter et al. (11) Diabetic/
SCID
mice
Acute MI CMPCs; EPDCs; both
CMPCs and
EPDCs; vehicle;
sham
13–20 (3 in sham) At the time
of MI
Intramyocardial via
thoracotomy; CMPCs
4  105; EPDCs 4 
105; dual therapy
included a total of 4 
105 CMPCs and EPDCs
6 weeks MRI EF [ in all cell groups (dual
therapy > single therapy)
EDV and ESV in dual therapy
comparable to sham
Latham et al. (12) NOD-SCID
mice
Acute MI hCACs; hCSCs; both
hCACs and hCSCs;
NHDFs; vehicle
9–13 1 week after
MI
Intramyocardial via
echocardiography
guidance; hCACs 1 
105; hCSCs 1  105;
hCACs and hCSCs in
dual therapy 0.5 
105 each
2, 3, and 15 weeks Echocardiography EF [ in all cell groups except
NHDFs (dual therapy >
single therapy)
Infarct size Y and capillary
density [ in dual therapy >
single therapy
Stem cell engraftment in dual
therapy4
Li et al. (13) Japanese
white
rabbit
Ischemic
cardiomyopathy
hUC-MSCs; both
hUC-MSCs and
hUCB-CD34þ;
vehicle
8 4 weeks after
MI
Intramyocardial via
thoracotomy; 5  106
hUC-MSCs; dual
therapy included 5 
106 hUC-MSCs and
5  105/kg CD34þ
4 weeks Echocardiography LV fractional shortening [
dual therapy > single
therapy > vehicle
Capillary density [ dual therapy
> single therapy
Ott et al. (14) Fisher rats Acute MI SM; BMMNCs cells;
both SM and
BMMNCs; vehicle
10–14 1 week after
MI
Intramyocardial via
thoracotomy; SM 1 
107; BMMNCs 1  107;
SM and BMMNCs 5 
106 each
8 weeks Echocardiography EF [ in SM and dual therapy
groups
EDV Y in dual therapy but not
single therapy compared
with baseline
Neovascularization [ in SM and
dual therapy groups >
BMMNCs
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TABLE 1 Continued
First Author (Ref. #) Host
Type of Heart
Disease Study Groups
No. of Animals
per Group
Time of Cell
Therapy
Dose and Route of
Administration
Follow-up Period
After Cell Therapy
Final Assessment
Modality Outcome
Memon et al. (15) Beagle dogs Acute MI SM; BMMNCs; both
SM and BMMNCs;
vehicle
4 At the time
of MI
Intramyocardial; SM 1 
108; BMMNCs 3 
106; dual therapy
included both the
above doses
4 weeks Echocardiography EF [ in dual therapy >
single therapy
Neovascularization [ dual
therapy > single therapy
Bonaros et al. (16) Nude rats Ischemic
cardiomyopathy
SM; hAC133þ cells;
both SM and
hAC133þ; vehicle
5 4 weeks after
MI
Intramyocardial via
thoracotomy; SM 1 
106; hAC133þ 1  106;
SM and hAC133þ
5  105 each
4 weeks Echocardiography EF [ in all cell groups; dual
therapy > single therapy
EDV Y in dual therapy > single
therapy
Infarct size Y and capillary
density [ in dual therapy >
single therapy
Suuronen et al. (17) Sprague-
Dawley
rats
Subacute MI MSCs; EPCs; both
MSCs and EPCs;
vehicle
6–8 3 weeks after
MI
Intramyocardial via
thoracotomy; MSCs
1  106; EPCs 1  106;
MSCs and EPCs
5  105 each
4 weeks Echocardiography EF [ in EPC group > MSC and
dual therapy groups
Arteriogenesis [ in EPC group >
MSC and dual therapy
groups
Infarct size in all cell groups and
vehicle4
Bonaros et al. (18) Nude rats Ischemic
cardiomyopathy
SM; hAC133þ cells;
both SM and
hAC133þ; vehicle
10–12 4 weeks after
MI
Intramyocardial via
thoracotomy; SM 1 
106; hAC133þ 1  106;
SM and hAC133þ
5  105 each
NA NA Stem cell engraftment [ in dual
therapy > single therapy
Angiogenesis [ in dual therapy
> single therapy
[ ¼ increased; Y ¼ decreased;4 ¼ no change; BMMNC ¼ bone marrow mononuclear cell; CMPC ¼ cardiomyocyte progenitor cell; dP/dt max ¼ the rate of left ventricular pressure rise in early systole; EF ¼ ejection fraction; EDV ¼ end-diastolic volume; EPC ¼
endothelial progenitor cell; EPDC ¼ epicardium-derived cells; ESV ¼ end-systolic volume; hCAC ¼ human circulatory angiogenic cell; hCPC ¼ human cardiac stem cell; hCSC ¼ human cardiac stem cell; hMSC ¼ human mesenchymal stem cells; hUC-MSC ¼
human umbilical cord–derived mesenchymal stem cells; hUCB-CD34þ ¼ human umbilical cord blood–derived CD34þ cells; hSVP ¼ human saphenous vein–derived pericyte progenitor; LV ¼ left ventricle; MI ¼ myocardial infarction; MRI ¼ magnetic resonance imaging;
MSC ¼ mesenchymal stem cell; NA ¼ not applicable; NHDF ¼ normal human dermal ﬁbroblasts; NOD ¼ nonobese diabetic; SCID ¼ severe combined immunodeﬁciency; SM ¼ skeletal myoblast.
J
A
C
C
V
O
L
.
6
6
,
N
O
.
1
8
,
2
0
1
5
B
olliand
G
hafghazi
N
O
V
E
M
B
E
R
3
,
2
0
1
5
:2
0
0
0
–
4
Im
portance
of
Studying
Cell
Therapy
in
Large
A
nim
als
20
0
3
Bolli and Ghafghazi J A C C V O L . 6 6 , N O . 1 8 , 2 0 1 5
Importance of Studying Cell Therapy in Large Animals N O V E M B E R 3 , 2 0 1 5 : 2 0 0 0 – 4
2004that have expertise with large animal models and
make these complex models available to the scientiﬁc
community. With such an infrastructure in place, all
investigators would have the opportunity to con-
duct studies of stem/progenitor cells in relevant and
rigorous preclinical models that would otherwise
be impossible for them to use. Such an infra-
structure would be analogous to the Consortium for
Preclinical Assessment of Cardioprotective Therapies,
which was developed to study reductions in infarct
size (19).
A massive disproportion currently exists between
rodent studies and large animal studies. There is aneed to increase the number of rigorous and relevant
preclinical studies, such as that by Karantalis et al.
(4). Until a publicly available consortium is developed
to rigorously evaluate stem/progenitor cells in clini-
cally relevant, large animal models, the progress of
cell therapy will be hindered, and translation into
human therapies will be difﬁcult.
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